W N Hunter
Affiliation: University of Dundee
Hunter W. Isoprenoid precursor biosynthesis offers potential targets for drug discovery against diseases caused by apicomplexan parasites. Curr Top Med Chem. 2011;11:2048-59 pubmed
..Particular attention will be paid to how these data inform on the apicomplexan orthologues concentrating on the enzymes from Plasmodium spp. these cause malaria, one the most important parasitic diseases in the world today. ..
Hunter W, Alphey M, Bond C, Schuttelkopf A. Targeting metabolic pathways in microbial pathogens: oxidative stress and anti-folate drug resistance in trypanosomatids. Biochem Soc Trans. 2003;31:607-10 pubmed
Hunter W. Structure-based ligand design and the promise held for antiprotozoan drug discovery. J Biol Chem. 2009;284:11749-53 pubmed publisher
..A structure-centric approach to support discovery of antiparasitic compounds promises much. Current strategies and benefits of a structure-based approach to support early stage drug discovery will be described. ..
Barrack K, Fyfe P, Finney A, Hunter W. Crystal structure of the C-terminal domain of tubulin-binding cofactor C from Leishmania major. Mol Biochem Parasitol. 2015;201:26-30 pubmed publisher
..Comparisons with an orthologous human GTPase activating protein match key residues involved in binding nucleotide and identify the face of the Î²-helix fold likely involved in interacting with the Î²-tubulin:GTP complex. ..
Hunter W. The non-mevalonate pathway of isoprenoid precursor biosynthesis. J Biol Chem. 2007;282:21573-7 pubmed
..Detailed knowledge of the pathway may also be exploited to genetically modify microorganisms and plants to produce compounds of agricultural and medical interest. ..
O Rourke P, Kalinowska Tłuścik J, Fyfe P, Dawson A, Hunter W. Crystal structures of IspF from Plasmodium falciparum and Burkholderia cenocepacia: comparisons inform antimicrobial drug target assessment. BMC Struct Biol. 2014;14:1 pubmed publisher
..The high degree of structural conservation in and around the IspF active site suggests that any structural model might be suitable to support a program of structure-based drug discovery. ..
Zoltner M, Ng W, Money J, Fyfe P, Kneuper H, Palmer T, et al
. EssC: domain structures inform on the elusive translocation channel in the Type VII secretion system. Biochem J. 2016;473:1941-52 pubmed publisher